Arvinas reports Q1 2026; FDA approves first PROTAC VEPPANU; licenses to Rigel

ARVINAS, INC.

2026-Q1 EPS reported -$0.90 vs consensus -$0.94 ▲ beat (+4.0%)

FDA approved VEPPANU (vepdegestrant) for ESR1m, ER+/HER2- advanced breast cancer — first PROTAC therapy approved.
Entered license agreement with Rigel Pharmaceuticals for exclusive global rights to VEPPANU; closing subject to HSR approval.
Cash and equivalents $614.9M at Mar 31, 2026 (Dec 31, 2025: $685.4M); cash runway into 2H 2028.
Randy Teel appointed President, CEO, and Director; Briggs Morrison elected Chair of the Board.
ARV-102 Phase 1: >50% LRRK2 degradation in CSF; ARV-806 KRAS G12D dose escalation complete; ARV-027 Phase 1 initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ARVINAS, INC. reported financial results for first quarter 2026.

Period: first quarter 2026
Result: reported results

Exact text from the filing

On May 12, 2026, Arvinas, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2026 and provided a corporate update.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

ARVINAS, INC. filing history →

Source: SEC EDGAR

accession 0001628280-26-033875

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.